Skip to content
10-K

Annual Report

KINNATE BIOPHARMA INC.

0001140361-24-016132

← back to feed
Filed
Mar 28, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2023 · Mar 20, 2024 47.23M sh
Shares Diluted FY 2023 · Dec 31, 2023 46.58M sh
Shares Diluted FY 2023 · Dec 31, 2022 44.07M sh
Capex FY 2023 · Dec 31, 2023 $0
Capex FY 2023 · Dec 31, 2022 $2.72M
Operating Cash Flow FY 2023 · Dec 31, 2023 −$100.04M
Operating Cash Flow FY 2023 · Dec 31, 2022 −$89.03M
Short Term Investments FY 2023 · Dec 31, 2023 $97.04M
Short Term Investments FY 2023 · Dec 31, 2022 $172.21M
Cash And Equivalents FY 2023 · Dec 31, 2023 $57M
Cash And Equivalents FY 2023 · Dec 31, 2022 $29.26M
Stockholders Equity FY 2023 · Dec 31, 2023 $159.33M
Stockholders Equity FY 2023 · Dec 31, 2022 $223.47M
Current Liabilities FY 2023 · Dec 31, 2023 $12M
Current Liabilities FY 2023 · Dec 31, 2022 $17.17M
Total Liabilities FY 2023 · Dec 31, 2023 $14.28M
Total Liabilities FY 2023 · Dec 31, 2022 $20.36M
Current Assets FY 2023 · Dec 31, 2023 $158.18M
Current Assets FY 2023 · Dec 31, 2022 $230.84M
Total Assets FY 2023 · Dec 31, 2023 $173.61M
Total Assets FY 2023 · Dec 31, 2022 $278.83M
Eps Diluted FY 2023 · Dec 31, 2023 −$2.42
Eps Diluted FY 2023 · Dec 31, 2022 −$2.64
Eps Basic FY 2023 · Dec 31, 2023 −$2.42
Eps Basic FY 2023 · Dec 31, 2022 −$2.64
Sga Expense FY 2023 · Dec 31, 2023 $28.24M
Sga Expense FY 2023 · Dec 31, 2022 $30.37M
Rd Expense FY 2023 · Dec 31, 2023 $90.77M
Rd Expense FY 2023 · Dec 31, 2022 $88.15M
Net Income FY 2023 · Dec 31, 2023 −$112.65M
Net Income FY 2023 · Dec 31, 2022 −$116.27M
Operating Income FY 2023 · Dec 31, 2023 −$121.18M
Operating Income FY 2023 · Dec 31, 2022 −$118.52M